(136 days)
eMotion Faros ECG Mobile & BodyGuardian Remote Monitoring System
Not Found
No
The summary explicitly states "Mentions AI, DNN, or ML: Not Found" and the description focuses on data collection and transmission without mentioning any analytical or diagnostic capabilities beyond basic arrhythmia detection.
No.
The device collects and transmits health parameters for monitoring and evaluation, but does not provide diagnosis or deliver any form of therapy.
No
The "Intended Use / Indications for Use" and "Device Description" sections explicitly state: "The Preventice BodyGuardian Remote Monitoring System does not provide any diagnosis."
No
The device description explicitly states that it collects health parameters from "a variety of commercially available, external plug in devices such as ECG sensors, Weight Scales, Blood Pressure Meters and Pulse Oximeters." This indicates the system relies on and integrates with external hardware components, making it more than just software.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device function: The description clearly states the device "collects and transmits health parameters" from external devices like ECG sensors, weight scales, blood pressure meters, and pulse oximeters. It also monitors cardiac arrhythmias. These are all measurements taken from the patient's body or external to it, not tests performed on samples taken from the body.
- No mention of samples: There is no mention of collecting or analyzing biological samples.
- Focus on monitoring and transmission: The primary function described is monitoring and transmitting data, not performing diagnostic tests on biological specimens.
Therefore, the BodyGuardian System falls under the category of a medical device for monitoring and data transmission, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The BodyGuardian System detects and monitors cardiac arrhythmias in ambulatory patients, when prescribed by a physician or other qualified healthcare professional. Not for use with pattended, In-hospital monitoring for life threatening arrhythmias.
The Preventice BodyGuardian Remote Monitoring System is intended for use with adult patients in clinical and non-clinical settings to collect and transmit health parameters to healthcare professionals for monitoring and evaluation.
Health parameters are collected from a variety of commercially available, external plug in devices such as ECG sensors. Weight Scales, Blood Pressure Meters and Pulse Oximeters. The Preventice BodyGuardian Remote Monitoring System does not provide any diagnosis.
Product codes (comma separated list FDA assigned to the subject device)
DSI
Device Description
Arrhythmia Detector and Alarm; Patient Physiological Monitor (with arrhythmia detection) The BodyGuardian System detects and monitors cardiac arrhythmias in ambulatory patients, when prescribed by a physician or other qualified healthcare professional. Not for use with patients requiring attended, In-hospital monitoring for life threatening arrhythmias.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
adult patients
Intended User / Care Setting
physician or other qualified healthcare professional, clinical and non-clinical settings
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-Clinical Testing: The following bench testing was conducted on the Preventice BG RMS: EMC and electrical safety testing Electrical and mechanical safety testing System safety testing Software verification and validation Performance testing Predicate device comparison tests Usability Testing Wireless transmission data quality and wireless coexistence testing The following testing has been performed to support substantial equivalence (see table 9): Biocompatibility for patient contact materials: Makrolon Versaflex See Appendix Q for specifications. The following quality assurance measures were applied during development of this device (appendices D, F, G): Failure Mode Effects Analysis/Hazard Analysis (FMEA) Design FMEAs for mechanical and RF designs. Performance Requirements Testing including Final System Verification and Validation Testing, ISO 60601 Testing, 3rd Edition.
Clinical Testing: This technology is not new, therefore a clinical study was not considered necessary prior to release. Additionally, there was no clinical testing required to support the medical device as the indications for use is equivalent to the predicate device. The substantial equivalence of the device is supported by the non-clinical testing.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
eMotion Faros ECG Mobile & BodyGuardian Remote Monitoring System
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.1025 Arrhythmia detector and alarm (including ST-segment measurement and alarm).
(a)
Identification. The arrhythmia detector and alarm device monitors an electrocardiogram and is designed to produce a visible or audible signal or alarm when atrial or ventricular arrhythmia, such as premature contraction or ventricular fibrillation, occurs.(b)
Classification. Class II (special controls). The guidance document entitled “Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm” will serve as the special control. See § 870.1 for the availability of this guidance document.
0
Image /page/0/Picture/12 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized graphic of three human profiles facing right, stacked on top of each other. The profiles are rendered in black and have a flowing, abstract design. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the graphic.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
September 17, 2015
Preventice Charlie Rector Director of RA/QA 2765 Commerce Drive NW, #220 Rochester, Minnesota 55901
Re: K151188
Trade/Device Name: BodyGuardian Remote Monitoring System Regulation Number: 21 CFR 870.1025 Regulation Name: Arrhythmia Detector and Alarm (Including ST-Segment Measurement and Alarm) Regulatory Class: Class II Product Code: DSI Dated: August 19, 2015 Received: August 20, 2015
Dear Charlie Rector:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply
1
with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Mitchell Stein
for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) Page 1 of 1 K151188
Device Name
BodyGuardian Remote Monitoring System
Indications for Use (Describe)
The BodyGuardian System detects and monitors cardiac arrhythmias in ambulatory patients, when prescribed by a physician or other qualified healthcare professional. Not for use with pattended, In-hospital monitoring for life threatening arrhythmias.
The Preventice BodyGuardian Remote Monitoring System is intended for use with adult patients in clinical and non-
clinical settings to collect and transmit health parameters to healthcare professionals for monitoring and evaluation.
Health parameters are collected from a variety of commercially available, external plug in devices such as ECG sensors.
Weight Scales, Blood Pressure Meters and Pulse Oximeters.
The Preventice BodyGuardian Remote Monitoring System does not provide any diagnosis.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
_ Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Druq Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
ທ 510(k) Summary
| 510(k) Summary (As required by section 21 CFR 807.92(c)) | |
|---|---|
| Submitter: | Preventice |
| 2765 Commerce Drive NW, Suite 220, Rochester, MN 55901 | |
| Contact Person: | Charles Rector |
| Director, RA/QA | |
| Telephone: 952/564-1465 | |
| Email: crector@preventice.com | |
| Date Prepared: | March 01, 2015 |
| Trade Name: | BodyGuardian Remote Monitoring System |
| Common/Usual Name: | Remote Monitoring System |
| Classification: | 21 CFR 870.1025 |
| Patient Physiological Monitor (with arrhythmia detection) | |
| Product Code: | DSI |
| Manufacturer: | Preventice |
| 2765 Commerce Drive NW, Suite 220, Rochester, MN 55901 | |
| Establishment Registration: | 3009883402 |
| Predicate Devices: | eMotion Faros ECG Mobile & |
| BodyGuardian Remote Monitoring System | |
| Device Description: | Arrhythmia Detector and Alarm; |
| Patient Physiological Monitor (with arrhythmia detection) | |
| The BodyGuardian System detects and monitors cardiac | |
| arrhythmias in ambulatory patients, when prescribed by a | |
| physician or other qualified healthcare professional. Not for use | |
| with patients requiring attended, In-hospital monitoring for life | |
| threatening arrhythmias. | |
| Intended Use | The Preventice BodyGuardian Remote Monitoring System is |
| intended for use with adult patients in clinical and non-clinical | |
| settings to collect and transmit health parameters to healthcare | |
| professionals for monitoring and evaluation. Health parameters | |
| are collected from a variety of commercially available, external | |
| plug in devices such as ECG sensors, Weight Scales, Blood Pressure | |
| Meters and Pulse Oximeters. The Preventice BodyGuardian | |
| Remote Monitoring System does not provide any diagnosis | |
| 510(k) Summary | (As required by section 21 CFR 807.92(c)) |
| Comparison of | |
| Technological | |
| Characteristics: | The predicate devices and the BodyGuardian System are small, |
| ambulatory cardiac monitors that record and transmit health | |
| monitors. They provide a data hub function that connects to | |
| commercially available devices such as weight scales, blood | |
| pressure monitors, pulse oximeters and other plug-in devices. | |
| Data is transmitted to an external device which, in turn, sends the | |
| data to a remote computer server that allows healthcare | |
| professionals to access and review the data. There are no | |
| fundamental differences between their technological | |
| characteristics. | |
| Non-Clinical Testing: | The following bench testing was conducted on the Preventice BG |
| RMS: | |
| EMC and electrical safety testing Electrical and mechanical safety testing System safety testing Software verification and validation Performance testing Predicate device comparison tests Usability Testing Wireless transmission data quality and wireless | |
| coexistence testing The following testing has been performed to support substantial | |
| equivalence (see table 9): Biocompatibility for patient contact materials: Makrolon Versaflex See Appendix Q for specifications. | |
| The following quality assurance measures were applied during | |
| development of this device (appendices D, F, G): Failure Mode Effects Analysis/Hazard Analysis (FMEA) Design FMEAs for mechanical and RF designs. Performance Requirements Testing including Final System | |
| Verification and Validation Testing, ISO 60601 Testing, 3rd | |
| Edition. | |
| Clinical Testing: | This technology is not new, therefore a clinical study was not |
| considered necessary prior to release. Additionally, there was no | |
| clinical testing required to support the medical device as the | |
| indications for use is equivalent to the predicate device. The | |
| substantial equivalence of the device is supported by the non- | |
| clinical testing. | |
| 510(k) Summary (As required by section 21 CFR 807.92(c)) | |
| Conclusion: | We conclude that the results of testing show the Preventice BG |
| RMS to be substantially equivalent to the predicate devices. | |
| The Preventice BG RMS has the same technological characteristics | |
| as the predicate devices in that all devices are intended to detect, | |
| transmit, and report digital data using similar computerized | |
| technology. The Preventice BG RMS has the same intended uses | |
| as the predicate devices in that all devices are intended for | |
| ambulatory monitoring. | |
| It has been shown in this 510(k) submission that the differences | |
| between the Preventice BG RMS and the predicates do not raise | |
| any questions regarding safety and effectiveness. The Preventice | |
| BG RMS, as designed and manufactured, is substantially | |
| equivalent to, and as safe and effective as, the referenced | |
| predicate devices. |
4
5